We investigated the efficacy, and safety of anti-CD30-MCC-DM1 in animal models to assess its potential as a therapeutic for the treatment of CD30-positive lymphomas, including L428, Karpas 299 and HH cell lines, which are derived from HL, ALCL, and CTCL, respectively. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.